

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



WIPO | PCT



(10) International Publication Number

WO 2017/064276 A1

(43) International Publication Date

20 April 2017 (20.04.2017)

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 9/127 (2006.01)

(21) International Application Number:

PCT/EP2016/074759

(22) International Filing Date:

14 October 2016 (14.10.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1518172.0 14 October 2015 (14.10.2015) GB

(71) Applicant: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED [MT/MT]; Palazzo Pietro Stiges, 103 Strait Street, Valletta, VLT1436 (MT).

(72) Inventors: HENRY, William; Leverton Licence Holdings Limited, Leverton House, 13 Bedford Square, London WC1B 3RA (GB). WOLF-GARRAWAY, Richard; Leverton Licence Holdings Limited, Leverton House, 13 Bedford Square, London WC1B 3RA (GB). MAYO, John; Leverton Licence Holdings Limited, Leverton House, 13 Bedford Square, London WC1B 3RA (GB).

(74) Agent: BASSIL, Nicholas; Kilburn & Strode LLP, 20 Red Lion Street, London WC1R 4PJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2017/064276 A1

(54) Title: COLLOIDAL PARTICLES FOR USE IN MEDICINE

(57) Abstract: The invention provides a composition comprising a colloidal particle comprising about 0.5 to 20 mole percent of an amphiphatic lipid derivatized with a biocompatible hydrophilic polymer for use in medicine, wherein said composition does not contain any pharmaceutically active agent.

COLLOIDAL PARTICLES FOR USE IN MEDICINE

The present invention relates to colloidal particles for use in medicine.

5 Many diseases in patients are characterised by sub-optimal levels in the blood or extracellular environment of an endogenous factor or hormone. The patient has a low level of the circulating endogenous factor or hormone which is insufficient to provide the necessary level of biological action or signalling to cells, tissues or organs. The patient may be characterised as suffering from a mild form of the disease in question.

10

For example, individuals with less than 1% active Factor VIII can be classified as having severe haemophilia A, those with 1–5% active Factor VIII as having moderate haemophilia A, and those with between 5–40% of normal levels of active clotting Factor VIII as having mild haemophilia A.

15

Diseases which are characterised by the absence of or an insufficient amount of an endogenous factor or hormone are traditionally treated by a replacement therapy in which the patient receives regular doses of the factor or hormone. However, subjects with mild to moderate forms of the disease do not require the same dosages of the therapeutic composition used to treat such disorders as for patients with none or almost none of the endogenous factor or hormone in question.

20

As in the treatment of any disease it is important to avoid prescribing a patient with too high a dose as many therapeutic agents can give rise to significant toxicities. Other problems with replacement therapy include the development of “resistance” through the formation of autoantibodies in the patient to the replacement factor or hormone.

25

Replacement therapies aim to restore biological function of the endogenous factor or hormone by administering an exogenous version of the factor or hormone which may be prepared by a variety of means, including chemical synthesis, recombinant DNA technology, donation from allogeneic donors or isolation from cadaveric sources. For example, the treatment of haemophilia relies on the

30

administration of blood factors and the treatment of diabetes uses insulin. Such therapies have used a variety of sources for the agent in question with various different formulations and routes of administration. However, factors and hormones obtained from donor sources carries with it the risk of contamination and synthetic routes of preparation are costly.

35

An example of this approach can be seen in the treatment of haemophilia with exogenous blood factors. Typically, blood factors have been prepared as pharmaceutical compositions for intravenous administration. The compositions have been based on the active protein, often conjugated to a polymer such as polyethylene glycol (PEG) to improve the half-life in circulation. Intravenous administration of PEGylated blood factors as therapeutic agents is therefore well understood and

widely accepted. Liposomal formulations of naked (i.e. unconjugated and without modification) blood factors such as Factor VIII and Factor IX substances are known also, see for example WO 95/04524.

Pharmaceutical compositions comprising Factor VIII and liposomes modified by the presence of 5 polyethylene glycol are described in WO 99/55306 in which the blood factor is not encapsulated in the liposome. However, the formulations are prepared for intravenous administration. Additional formulations of other proteins are described in WO 2004/091723 where the proteins include blood clotting factors. The proteins are said to bind to the liposomes in a non-covalent manner through interaction with the polyethylene glycol present on the surface of the liposomes. However, the 10 formulations of blood clotting factors prepared according to the examples of this document are also for intravenous administration.

Other examples of formulations of blood factors, Factor VIII and Factor VIIa, present as a conjugate 15 with PEG are shown in WO 2011/135307 and WO 2011/135308 respectively where the actual formulations prepared were for intravenous administration. WO 2013/156488 also describes a dosage form of modified therapeutic agents, including blood factors such as Factor VIII (FVIII) and Factor VIIa (FVIIa), for subcutaneous administration.

The blood factor Factor VIII has also been found to be capable of association with PEGylated 20 liposomes, i.e. the blood factor is not encapsulated inside the liposome (Baru *et al* Thromb. Haemost, 93, pages 1061-1068, (2005)). However, the compositions of FVIII were only prepared as formulations for intravenous administration.

Further studies by Peng *et al* in *The AAPS Journal*, 14(1), pages 25-42 (2011) disclose an alternative 25 approach based on FVIII encapsulated in liposomes which are subsequently PEGylated by passively adding PEG to the liposomes after preparation. In one experiment in Peng *et al* the liposomal formulation is administered subcutaneously (SC) to investigate immunogenicity but there is no suggestion of a therapeutic purpose to this administration. In Peng *et al* there is also a specific reference to the paper of Baru *et al* (2005) and a statement that the approach of Baru *et al* "exposed 30 FVIII to plasma components such as proteases and IgGs". Liposomes prepared according to the method of Baru *et al* (2005) containing recombinant Factor VIII have been administered intravenously to subjects (Spira *et al* *Blood*, 108 (12), pages 3668-3673 (2012)).

It would, therefore, be preferable for a patient suffering from a mild to moderate form of such a 35 disease to have a means of supplementing the endogenous levels of the factor or hormone in question in such a way that external sources of the factor or hormone were not necessarily required.

According to the present invention there is provided a composition comprising a colloidal particle comprising approximately 0.5 to 20 mole percent of an amphipathic lipid derivatized with a 40 biocompatible hydrophilic polymer for use in medicine. The composition consists of the colloidal

particles without any other pharmaceutically active agent being present. Such pharmaceutically active agents are defined as drugs, substances, molecules or compounds having a pharmacological effect on the body of a subject.

5 The composition comprising the colloidal particles of the invention may be used in the treatment of a disease in a subject characterised by insufficient levels of an endogenous factor or hormone in the subject. The disease may result from a loss of function or partial loss of function of a gene or genes connected with the production of the endogenous factor or hormone.

10 The compositions of the present invention therefore provide for the protection and prolongation of the activity of an endogenous biologically active polypeptide or protein. The invention provides for the therapy of a disease or a condition without the need for administration of exogenous protein with or without further derivatization. Where the composition is administered topically the invention also means that a subject is not required to receive any injections as in conventional therapies in order to 15 maintain a therapeutically effective circulating level of the biologically active polypeptide or protein. If the subject is already regularly receiving an exogenous injection of a biologically active polypeptide or protein, the composition will prolong the life of such polypeptide or protein within the body enabling either the administered dose of such polypeptide or protein to be reduced, the intervals between doses to be increased or a combination of both these benefits.

20 The disease may be selected from the group consisting of a blood factor disease, an endocrine disorder or a hormone deficiency.

25 The blood factor disease may be a haemophilia (haemophilia A, B or C), von Willebrand Disease, Factor V deficiency, Factor X deficiency, Factor XII deficiency.

The endocrine disorder may be acromegaly, Addison's Disease, Cushing's Syndrome, De Quervain's Thyroiditis, obesity, diabetes mellitus (Type 1 diabetes or Type 2 diabetes), diabetes insipidus, Goiter, Graves' Disease, Growth Disorders, Growth Hormone Deficiency, Hashimoto's Thyroiditis, 30 Hyperglycaemia, Hyperparathyroidism, Hypoglycaemia, Hypoparathyroidism, Low Testosterone, Menopause, Osteoporosis, Parathyroid Diseases, Pituitary Disorders, Polycystic Ovary Syndrome, Prediabetes, Turner Syndrome.

35 The colloidal particles may be substantially neutral and the polymer may carry substantially no net charge. The colloidal particles may have a mean particle diameter of between about 0.03 to about 0.4 microns (μm), for example having a mean particle diameter of approximately 0.1 microns (μm). A mean particle diameter in this range may increase the circulation time of the particles *in vivo* and prevent their adsorption by the reticuloendothelial system (RES).

The colloidal particles of the invention are typically in the form of lipid vesicles or liposomes as are well known in the art. References to colloidal particles in the present specification include liposomes and lipid vesicles unless the context specifies otherwise.

- 5 In the colloidal particles, the amphipathic lipid may be a phospholipid from natural or synthetic sources. The amphipathic lipid may comprise approximately 0.5 to about 20 mole percent (%) of the particles, for example approximately about 1 to 20%, or about 1 to 6%, or about 3%.

An “amphipathic lipid” refers to a substance including a hydrophilic region and a hydrophobic region, 10 such as phospholipids. Amphipathic lipids can be zwitterionic phospholipids, zwitterionic lipids, lipids having a net negative charge, and lipids having a net positive charge. For example, amphipathic lipids include, but are not limited to, phosphatidylcholines, phosphatidylserines, phosphatidylethanolamines, phosphatidylinositol, sphingomyelin, soybean lecithin (soya lecithin), egg lecithin, lysophosphatidylcholines, lysophosphatidylethanolamines, phosphatidylglycerols, 15 phosphatidylserines, phosphatidylinositol, phosphatidic acids, cardiolipins, acyl trimethylammonium propane, diacyldimethylammonium propane, stearylamine, ethyl phosphatidylcholine and the like. Soya lecithin is a combination predominantly of naturally-occurring phospholipids; phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylinositol (PI).

- 20 Suitable examples of such amphipathic lipids include a phosphatidylethanolamine (PE), a carbamate-linked uncharged lipopolymer or aminopropanediol distearoyl (DS), or mixtures thereof.

Examples of phosphatidylethanolamine phospholipids include 1,2-Dierucoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dilauroyl-sn-glycero-3-phosphoethanolamine, 1,2-Dimyristoyl-sn-glycero-25 3-phosphoethanolamine, 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine. A suitable example of phosphatidyl ethanolamine (PE) may be 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine (DSPE). The purpose of the biocompatible hydrophilic polymer is to sterically stabilize the SUVs, thus preventing fusion of the vesicles *in vitro*, 30 and allowing the vesicles to escape adsorption by the RES *in vivo*.

The colloidal particles may further comprise a second amphipathic lipid obtained from either natural or synthetic sources. The second amphipathic lipid may be a phosphatidylcholine (PC). Examples of phosphatidylcholine phospholipids include 1,2-Didecanoyl-sn-glycero-3-phosphocholine, 1,2-Dierucoyl-sn-glycero-3-phosphocholine, 1,2-Dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-Dilauroyl-sn-glycero-3-phosphocholine, 1,2-Dimyristoyl-sn-glycero-3-phosphocholine, 1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-Distearoyl-sn-glycero-3-phosphocholine, 1-Myristoyl-2-palmitoyl-sn-glycero 3-phosphocholine, 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine, 1-Palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine, 1-Palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1-Palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine, 1-Stearoyl-

2-myristoyl-*sn*-glycero-3-phosphocholine, 1-Stearoyl-2-oleoyl-*sn*-glycero-3-phosphocholine, 1-Stearoyl-2-palmitoyl-*sn*-glycero-3-phosphocholine. A suitable example of phosphatidyl choline (PC) may be palmitoyl- oleoyl phosphatidyl choline (POPC) or soy phosphatidyl choline. Other natural sources of phosphatidylcholine include egg phosphatidylcholine. The phosphatidylcholine may be 5 hydrogenated or non-hydrogenated.

In one embodiment, the pharmaceutical composition may be composed of colloidal particles which comprise palmitoyl- oleoyl phosphatidyl choline (POPC) and 1,2-distearoyl-*sn*-glycero-3-phosphoethanol-amine (DSPE) in a molar ratio (POPC:DSPE) of from 85 to 99:15 to 1. In some 10 cases, the molar ratio of POPC:DSPE may be from 90 to 99:10 to 1. In one embodiment, the molar ratio of POPC:DSPE may be 97:3. A molar ratio of 97:3 of these lipids is equivalent to a 97:10 weight ratio.

In an alternative embodiment, the pharmaceutical composition of the invention may be supplemented 15 with cholesterol.

The biocompatible polymer may have a molecular weight of between about 500 to about 5000 Daltons, for example approximately 2000 Daltons.

20 The biocompatible hydrophilic polymer used according to the invention may be selected from the group consisting of polyalkylethers, polylactic acids and polyglycolic acids. The biocompatible hydrophilic polymer may be polyethylene glycol (PEG). The polyethylene glycol as used in the compositions of the invention may have a molecular weight of between about 500 to about 5000 Daltons, for example it may have a molecular weight of approximately 1000, 2000, or 3000 Daltons. 25 In one embodiment the molecule weight of the PEG may be 2000 Daltons. The polyethylene glycol may be branched or unbranched.

An example of a suitable derivatized amphipathic lipid may be 1,2-distearoyl-*sn*-glycero-3-phosphoethanol-amine-N-[poly-(ethyleneglycol)]. If the PEG has a molecular weight of 2000 Daltons, 30 the derivatized amphipathic lipid may be described as 1,2-distearoyl-*sn*-glycero-3-phosphoethanol-amine-N-[poly-(ethyleneglycol)-2000] (DSPE-PEG 2000).

The concentration of the derivatized amphipathic lipid in the final formulation of colloidal particles may be adjusted accordingly to suit the desired properties of the composition. However, suitable 35 concentrations may be from 5.0mg/mL to 15mg/mL, for example 7.5mg/mL to 12.5mg/mL, or 7.6mg/mL to 9.0mg/mL. The overall content of lipid in the final formulation may be in the range of from 4% to 12%, for example 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11% or 12%.

The composition may comprise any suitable excipient, buffer and/or adjuvant and may be formulated 40 as a pharmaceutical composition. Examples of such excipients, buffers and/or adjuvants, include

phosphate buffered saline (PBS), potassium phosphate, sodium phosphate and/or sodium citrate. Other biological buffers can include PIPES, MOPS etc.

5 Suitable pH values for the composition include any generally acceptable pH values for administration *in vivo*, such as for example pH 5.0 to pH 9.0, suitably from pH 6.8 to pH 7.2, or pH 7.0.

The present inventors have surprisingly found that formulations of colloidal particles (liposomes) derivatized with a biocompatible polymer can be successfully administered and achieve a therapeutically effective dose in a subject. Suitably, the biocompatible polymer is polyethylene glycol.

10

This aspect of the invention therefore extends to a method of treatment of a subject suffering from a disease or condition as defined above, comprising administering to the subject a composition comprising colloidal particles as defined above. The invention includes uses of such colloidal particles in the manufacture of a medicament for the treatment of such a disease or condition.

15

Without wishing to be bound by theory, it is believed that that the colloidal particles used in accordance with the present invention can potentiate the activity of a factor or hormone in a subject. In many diseases, the symptoms of the disease can be manifested when a subject has sub-optimal levels of the factor or hormone.

20

Where the factor is a blood factor it may be selected from the group consisting of Factor VII, Factor VIIa, Factor VIII, Factor IX, Factor X, Factor Xa, Factor XI, Factor VIIa, Factor V, Factor XIII, von Willebrand's Factor and Protein C. In some embodiments the blood coagulation factor may be suitably Factor VII, Factor VIII or Factor IX.

25

Other factors or hormones include but are not limited to, calcitonin, erythropoietin (EPO), granulocyte colony stimulating factor (GCSF), thrombopoietin (TPO), alpha-1 proteinase inhibitor, granulocyte macrophage colony stimulating factor (GMCSF), growth hormone, heparin, human growth hormone (HGH), growth hormone releasing hormone (GHRH), interferon alpha, interferon beta, interferon 30 gamma, interleukin-1 receptor, interleukin-2, interleukin-1 receptor antagonist, interleukin-3, interleukin-4, interleukin-6, luteinizing hormone releasing hormone (LHRH), insulin, pro-insulin, amylin, C-peptide, somatostatin, vasopressin, follicle stimulating hormone (FSH), insulin-like growth factor (IGF), insulintropin, macrophage colony stimulating factor (M-CSF), nerve growth factor (NGF), tissue growth factors, keratinocyte growth factor (KGF), glial growth factor (GGF), tumor necrosis 35 factor (TNF), endothelial growth factors, parathyroid hormone (PTH), glucagon-like peptide (GLP).

The factor may also be an antibody or an antibody fragment for example; a single-domain antibody, V_L, V_H, Fab, F(ab')₂, Fab', Fab3, scFv, di-scFv, sdAb, Fc and/or combinations thereof.

A variety of known coupling reactions may be used for preparing vesicle forming lipids derivatized with hydrophilic polymers. For example, a polymer (such as PEG) may be derivatized to a lipid such as phosphatidylethanolamine (PE) through a cyanuric chloride group. Alternatively, a capped PEG may be activated with a carbonyl diimidazole coupling reagent, to form an activated imidazole compound. A carbamate-linked compound may be prepared by reacting the terminal hydroxyl of MPEG (methoxyPEG) with p-nitrophenyl chloroformate to yield a p-nitrophenyl carbonate. This product is then reacted with 1-amino-2,3-propanediol to yield the intermediate carbamate. The hydroxyl groups of the diol are acylated to yield the final product. A similar synthesis, using glycerol in place of 1-amino-2, 3-propanediol, can be used to produce a carbonate-linked product, as described in WO 01/05873. Other reactions are well known and are described, e.g. in US 5,013,556.

Colloidal particles (liposomes) can be classified according to various parameters. For example, when the size and number of lamellae (structural parameters) are used as the parameters then three major types of liposomes can be described: Multilamellar vesicles (MLV), small unilamellar vesicles (SUV) and large unilamellar vesicles (LW).

MLV are the species which form spontaneously on hydration of dried phospholipids above their gel to liquid crystalline phase transition temperature (cm). The size of the MLVs is heterogeneous and their structure resembles an onion skin of alternating, concentric aqueous and lipid layers.

SUV are formed from MLV by sonication or other methods such as extrusion, high pressure homogenisation or high shear mixing and are single layered. They are the smallest species with a high surface-to-volume ratio and hence have the lowest capture volume of aqueous space to weight of lipid.

The third type of liposome LUV has a large aqueous compartment and a single (unilamellar) or only a few (oligolamellar) lipid layers. Further details are disclosed in D. Lichtenberg and Y. Barenholz, in *"Liposomes: Preparation, Characterization, and Preservation, in Methods of Biochemical Analysis"*, Vol. 33, pp. 337 – 462 (1988).

As used herein the term "loading" means any kind of interaction of the biopolymeric substances to be loaded, for example, an interaction such as encapsulation, adhesion (to the inner or outer wall of the vesicle) or embedding in the wall with or without extrusion of the biopolymeric substances.

As used herein and indicated above, the term "liposome" refers to colloidal particles and is intended to include all spheres or vesicles of any amphipathic compounds which may spontaneously or non-spontaneously vesiculate, for example phospholipids where at least one acyl group replaced by a complex phosphoric acid ester. The liposomes may be present in any physical state from the glassy state to liquid crystal. Most triacylglycerides are suitable and the most common phospholipids suitable for use in the present invention are the lecithins (also referred to as phosphatidylcholines (PC)), which

are mixtures of the diglycerides of stearic, palmitic, and oleic acids linked to the choline ester of phosphoric acid. The lecithins are found in all animals and plants such as eggs, soybeans, and animal tissues (brain, heart, and the like) and can also be produced synthetically. The source of the phospholipid or its method of synthesis are not critical, any naturally occurring or synthetic phosphatide can be used.

Examples of specific phosphatides are L-a-(distearoyl) lecithin, L-a-(dipalmitoyl) lecithin, L-a-phosphatide acid, L-a-(dilauroyl)-phosphatidic acid, L-a(dimyristoyl) phosphatidic acid, L-a(dioleoyl)phosphatidic acid, DL-a (di- palmitoyl) phosphatidic acid, L-a(distearoyl) phosphatidic acid, and the various types of L-a-phosphatidylcholines prepared from brain, liver, egg yolk, heart, soybean and the like, or synthetically, and salts thereof. Other suitable modifications include the controlled peroxidation of the fatty acyl residue cross-linkers in the phosphatidylcholines (PC) and the zwitterionic amphipathates which form micelles by themselves or when mixed with the PCs such as alkyl analogues of PC.

15

The phospholipids can vary in purity and can also be hydrogenated either fully or partially. Hydrogenation reduces the level of unwanted peroxidation, and modifies and controls the gel to liquid/crystalline phase transition temperature (try) which effects packing and leakage.

20

The liposomes can be "tailored" to the requirements of any specific reservoir including various biological fluids, maintains their stability without aggregation or chromatographic separation, and remains well dispersed and suspended in the injected fluid. The fluidity *in situ* changes due to the composition, temperature, salinity, bivalent ions and presence of proteins. The liposome can be used with or without any other solvent or surfactant.

25

Generally suitable lipids may have an acyl chain composition which is characteristic, at least with respect to transition temperature (Tm) of the acyl chain components in egg or soybean PC, i.e., one chain saturated and one unsaturated or both being unsaturated. However, the possibility of using two saturated chains is not excluded.

30

The liposomes may contain other lipid components, as long as these do not induce instability and/or aggregation and/or chromatographic separation. This can be determined by routine experimentation.

35

The biocompatible hydrophilic polymer may be physically attached to the surface of the liposome, or inserted into the membrane of the liposome. The polymer may therefore be covalently bound to the liposome.

Either or both of the colloidal particle or the biologically active polypeptide or protein may be modified in order to modulate the dynamics of the association between the colloidal particle and the

polypeptide or protein. Such modulation may be achieved by customising regions or binding sequences on the colloidal particle or the biologically active polypeptide or protein.

5 A variety of methods for producing the modified liposomes which are unilamellar or multilamellar are known and available (see Lichtenberg and Barenholz, (1988)):

- 10 1. A thin film of the phospholipid is hydrated with an aqueous medium followed by mechanical shaking and/or ultrasonic irradiation and/or extrusion through a suitable filter;
2. Dissolution of the phospholipid in a suitable organic solvent, mixing with an aqueous medium followed by removal of the solvent;
3. Use of gas above its critical point (i.e., freons and other gases such as CO₂ or mixtures of CO₂ and other gaseous hydrocarbons) or
4. Preparing lipid detergent mixed micelles then lowering the concentration of the detergents to a level below its critical concentration at which liposomes are formed.

15

In general, such methods produce liposomes with heterogeneous sizes from about 0.02 to 10 μm or greater. Since liposomes which are relatively small and well defined in size are preferred for use in the present invention, a second processing step defined as "liposome down-sizing" can be used for reducing the size and size heterogeneity of liposome suspensions.

20

The liposome suspension may be sized to achieve a selective size distribution of vesicles in a size range less than about 5 μm , for example < 0.4 μm . In one embodiment of the invention, the colloidal particles have an average particle size diameter of from about 0.03 to 0.4 microns (μm), suitably around 0.1 microns (μm).

25

Liposomes in this range can readily be sterilized by filtration through a suitable filter. Smaller vesicles also show less of a tendency to aggregate on storage, thus reducing potentially serious blockage or plugging problems when the liposome is injected intravenously or subcutaneously. Finally, liposomes which have been sized down to the submicron range show more uniform distribution.

30

Several techniques are available for reducing the sizes and size heterogeneity of liposomes, in a manner suitable for the present invention. Ultrasonic irradiation of a liposome suspension either by standard bath or probe sonication produces a progressive size reduction down to small unilamellar vesicles (SUVs) between 0.02 and 0.08 μm in size.

35

Homogenization is another method which relies on shearing energy to fragment large liposomes into smaller ones. In a typical homogenization procedure the liposome suspension is recirculated through a standard emulsion homogenizer until selected liposome sizes, typically between about 0.1 and 0.5 μm are observed. In both methods, the particle size distribution can be monitored by conventional 40 laser-beam particle size determination.

Extrusion of liposomes through a small-pore polycarbonate filter or equivalent membrane is also an effective method for reducing liposome sizes down to a relatively well-defined size distribution whose average is in the range between about 0.02 and 5 μm , depending on the pore size of the membrane.

5

Typically, the suspension is cycled through one or two stacked membranes several times until the desired liposome size distribution is achieved. The liposome may be extruded through successively smaller pore membranes to achieve a gradual reduction in liposome size.

10 Centrifugation and molecular sieve chromatography are other methods which are available for producing a liposome suspension with particle sizes below a selected threshold less than 1 μm . These two respective methods involve preferential removal of large liposomes, rather than conversion of large particles to smaller ones. Liposome yields are correspondingly reduced.

15 The size-processed liposome suspension may be readily sterilized by passage through a sterilizing membrane having a particle discrimination size of about 0.4 μm , such as a conventional 0.45 μm depth membrane filter. The liposomes are stable in lyophilized form and can be reconstituted shortly before use by taking up in water.

20 Suitable lipids for forming liposomes are described above. Suitable examples include but are not limited to phospholipids such as dimirystoylphosphatidylcholine (DMPC) and/or dimirystoyl - phosphatidylglycerol (DMPG), egg and soybean derived phospholipids as obtained after partial or complete purification, directly or followed by partial or complete hydrogenation.

25 The following four methods are described in WO 95/04524 and are generally suitable for the preparation of the colloidal particles (liposomes) used in accordance with the present invention.

Method A

- a) mixing amphipathic substances, such as lipids suitable for forming vesicles in water-immiscible organic solvents
- b) removing of the solvent in presence of a solid support, alternatively, dried amphipathic substances or mixtures thereof can be used in any form (powder, granular, etc.) directly,
- c) taking up the product of step b) into a solution of the biopolymeric substances in a physiologically compatible solution
- d) adding an organic solvent having solubilizing or dispersing properties, as well as
- e) drying the fraction obtained in step d) under conditions retaining the function of the biopolymeric substances.

According to step a) of Method A amphipathic substances suitable for forming vesicles as mentioned above are mixed in a water-immiscible organic solvent. The water-immiscible organic solvent may be

a polar-protic solvent such as fluorinated hydrocarbons, chlorinated hydrocarbons and the like.

In step b) of the method of the invention the solvent is removed in presence of a solid support. The solid support may be an inert organic or inorganic material having a bead-like structure. The material 5 of the inorganic support material may be glass and the organic material can be TeflonTM or other similar polymers.

The step c) of Method A of the invention is for taking up the product of step b) into a solution of the substances to be encapsulated in a physiologically compatible solution.

10

The physiological compatible solution may be equivalent to a sodium chloride solution up to about 1.5 by weight. It is also possible to use other salts as long as they are physiologically compatible e.g. as a cryoprotectant e.g., sugars and/or amino acids. For example, lactose, sucrose or trehalose may be used as a cryoprotectant.

15

Optionally, between step a) and b) a step of virus inactivation, sterilizing, depyrogenating, filtering the fraction or the like of step a) can be provided. This might be advantageous in order to have a pharmaceutically acceptable solution at an early stage of the preparation.

20

The step d) of the Method A is adding an organic solvent having solubilizing or dispersing properties.

The organic solvent may be an organic polar-protic solvent miscible with water. Lower aliphatic alcohols having 1 to 5 carbon atoms in the alkyl chain can also be used, such as tertiary butanol (tert-butanol).

25

Optionally, subsequent to step d), virus inactivation sterilizing and/or portioning of the fraction yielded after step d) can be carried out.

30

The step e) of the present invention is drying the fraction obtained in step d) under conditions retaining the function of the substance to be loaded. One method for drying the mixture is lyophilization. The lyophilization may be carried out in presence of a cryoprotectant, for example, lactose or other saccharides or amino acids. Alternatively, evaporation or spray-drying can be used.

35

The dried residue can then be taken up in an aqueous medium prior to use. After taking up of the solid it forms a dispersion of the respective liposomes. The aqueous medium may contain a saline solution and the dispersion formed can optionally be passed through a suitable filter in order to down size the liposomes if necessary. Suitably, the liposomes may have a size of 0.02 to 5 µm, for example in the range of < 0.4 µm.

40

The compositions of the invention can also be an intermediate product obtainable by isolation of

either fraction of step c) or d) of the method A. Accordingly, the formulation of the invention also comprises an aqueous dispersion obtainable after taking up the product of step e) of method A in water in form of a dispersion (liposomes in aqueous medium).

5 Alternatively, the pharmaceutical compositions of the invention are also obtainable by the following methods which are referred to as Methods B, C, D and E.

Method B

This method comprises also the steps a), b) and c) of the Method A. However, step d) and e) of
10 Method A are omitted.

Method C

In Method C step d) of method A is replaced by a freeze and thaw cycle which has to be repeated at least two times. This step is well-known in prior art to produce liposomes.

15

Method D

Method D excludes the use of any osmotic component. In method D the steps of preparation of vesicles, admixing and substantially salt free solution of the substances to be loaded and co-drying of the fractions thus obtained is involved.

20

Method E

25

Method E is simpler than methods A - D described above. It requires dissolving the compounds used for liposome preparation (lipids antioxidants, etc.) in a polar-protic water miscible solvent such as tert.-butanol. This solution is then mixed with an aqueous solution or dispersion containing the blood factor. The mixing is performed at the optimum volume ratio required to maintain activity .

The mixture is then lyophilized in the presence or absence of cryoprotectant. Rehydration is required before the use of the liposomal formulation. These liposomes are multilamellar, their downsizing can be achieved by one of the methods described in WO 95/04524.

30

35

As used herein, the term "treatment" includes any regime that can benefit a human or a non-human mammal. The treatment of "non-human mammals" extends to the treatment of domestic mammals, including horses and companion animals (e.g. cats and dogs) and farm/agricultural animals including members of the ovine, caprine, porcine, bovine and equine families. The treatment may be in respect of any existing condition or disorder, or may be prophylactic (preventive treatment). The treatment may be of an inherited or an acquired disease. The treatment may be of an acute or chronic condition.

Levels of activity in the blood coagulation cascade may be measured by any suitable assay, for example the Whole Blood Clotting Time (WBCT) test or the Activated Partial Thromboplastin Time (APTT).

- 5 The Whole Blood Clotting Time (WBCT) test measures the time taken for whole blood to form a clot in an external environment, usually a glass tube or dish.

The Activated Partial Thromboplastin Time (APTT) test measures a parameter of part of the blood clotting pathway. It is abnormally elevated in haemophilia and by intravenous heparin therapy. The 10 APTT requires a few millilitres of blood from a vein. The APTT time is a measure of one part of the clotting system known as the "intrinsic pathway". The APTT value is the time in seconds for a specific clotting process to occur in the laboratory test. This result is always compared to a "control" sample of normal blood. If the test sample takes longer than the control sample, it indicates decreased clotting 15 function in the intrinsic pathway. General medical therapy usually aims for a range of APTT of the order of 45 to 70 seconds, but the value may also be expressed as a ratio of test to normal, for example 1.5 times normal. A high APTT in the absence of heparin treatment can be due to haemophilia, which may require further testing.

The invention also provides a kit of parts comprising a composition of the invention, and an 20 administration vehicle including injectable solutions for administration, said kit suitably comprising instructions for use thereof.

The invention therefore may also suitable provide a dosage form of a composition of the invention. Such dosage forms may be provided as suitable containers or vials containing the appropriate dose 25 for a patient.

A dosage up to 2.000 mg/liposomes lipid per kg body weight can be administered to patients.

Accordingly, in another aspect of the present invention, the volume of the formulation for delivery into 30 a patient may be no more than 2ml. Suitably, the delivery volume may be 5µl, 10µl, 25µl, 50µl, 100µl, 250µl, 500µl, 750µl, or 1ml. In alternative embodiments the volume of the formulation for delivery may be no more than 1.5ml, 2ml, 2.5ml, 3.0ml or 3.5ml.

The formulations of the invention may be for administration at least once per day, at least twice per 35 day, about once per week, about twice per week, about once per two weeks, or about once per month.

The composition comprising colloidal particles for use according to the invention may be formulated for administration by any convenient route, such as subcutaneous, intravenous or topical

administration. The colloidal particles may therefore be formulated as a pharmaceutical composition, wherein the composition does not contain any pharmaceutically active agent.

A formulation suitable for topical, subcutaneous or intravenous administration may suitably be

5 prepared as an aqueous or substantially aqueous formulation. The formulation may comprise such additional salts, preservatives and stabilisers and/or excipients or adjuvants as required. The dosage forms of the invention may be provided as anhydrous powders ready for extemporaneous formulation in a suitable aqueous medium.

10 Suitably such dosage forms can be formulated as buffered aqueous formulations. Suitable buffer solutions may include, but are not limited to amino acids (for example histidine), salts of inorganic acids and alkali metals or alkaline earth metals, (for example sodium salts, magnesium salts, potassium salts, lithium salts or calcium salts – exemplified as sodium chloride, sodium phosphate or sodium citrate). Other components such as detergents or emulsifiers (for example, Tween 80[®] or any 15 other form of Tween[®]) may be present and stabilisers (for example benzamidine or a benzamidine derivative). Excipients such as sugars, (for example sucrose) may also be present. Suitable values for pH are physiological pH, e.g. pH 6.8 to 7.4 or pH 7.0. The pH may be adjusted accordingly with a suitable acid or alkali, for example hydrochloric acid. Liquid dosage forms may be prepared ready for use in such administration vehicles, for example as 3.5ml or 7.0ml vials.

20

In one particular embodiment, there is provided a composition for intravenous or subcutaneous administration for use in accordance with the invention as follows:

- 50mM sodium citrate

25

- pH 7.0

- 100mM phospholipids – 97:3 molar ratio of palmitoyl- oleoyl phosphatidyl choline (POPC) and 1,2- distearoyl-sn-glycero-3phosphoethanol-amine-N-[poly-(ethyleneglycol)-2000] (DSPE-PEG 2000).

30

Formulations for topical administration may be formulated using a topical gel comprising one or more components selected from the group consisting of: surfactants, preservatives, thickeners, buffers, and water. In one embodiment, the surfactant may be a nonionic surfactant selected from the group consisting of: polyoxyethylene sorbitans, polyhydroxyethylene stearates or polyhydroxyethylene laurylethers, optionally the surfactant is polysorbate 80 (Tween 80). The ratio of phospholipid to 35 surfactant may be from 30:1, to 15:1, 10:1, suitably 15:1, 8:1, or 2:1. The surfactant concentration may be from 0.25% to 5% by weight, for example 1% to 3%, 1 to 2%, some exemplary values may be 0.47%, 0.85%, or 3.5%. Examples of such formulations for topical administration are described in WO 2010/140061 and WO 2011/022707.

The invention will now be further described by way of reference to the following examples which are present for the purposes of illustration only and are not be taken as limitations to the invention:

Example 1: Synthesis of liposomes

5 Mixed lipids were prepared from palmitoyl-oleoyl phosphatidyl choline (POPC) and 1,2- distearoyl-sn-glycero-3-phosphoethanol-amine-N-[poly-(ethyleneglycol)-2000] derivatized with PEG-2000 (PEG with molecular weight 2000 Daltons) (DSPE-PEG 2000), as follows:

Molecular weight of POPC: 760.08g/mol

10 Molecular weight of DSPE-2kPEG: 2789.5g/mol

The final preparation had a concentration of 100mM phospholipids. A 15% w/v mixture of lipids was made with a 97:3 molar ratio of POPC:DSPE-2kPEG. The following were weighed and mixed:

15 2.04g POPC
0.232g DSPE-2kPEG
14.9mL tert-butanol (melted in a 35°C water bath), all placed in a 100mL Schott bottle.

20 The mixture was maintained at 35°C in a water bath and stirred intermittently until all solids had dissolved/dispersed. The final material was a clear colourless mixture. The mixture was frozen at -80°C overnight.

25 The operation was maintained in a fume hood to allow containment during the post-use clean-up of dried/condensed solvent. The Christ Alpha 1-2 LD freeze-drier and vacuum pump were warmed up for 20 minutes, and the frozen lipid/solvent mixture was removed from -80°C storage and dried overnight.

30 The dried lipids were recovered from the drier the following morning. They appeared as a dry crystalline cake. A 100mM lipid solution was required for further processing. The quantities of lipid present calculate through as around 82 μ moles of DSPE-2kPEG and 2.69mmoles of POPC; so around 2.77mmoles of lipids. Thus 27.7mL of diluent was required. 27.7mL of 50mM sodium citrate buffer was added to the dried lipids, and the resulting mixture was stirred and heated to around 35°C. After around 120 minutes, a white emulsion with no obvious large solids resulted. This was subjected to extrusion as below.

35 A Sartorius 47mm stainless steel pressure filtration housing was assembled and wrapped with a water jacket (wrapped tubing fed via a thermocirculator) maintained at 35°C. The housing was fitted with a polycarbonate track-etched membrane (details below), covered by a glass-fibre prefilter (Whatman GF/D). The emulsion was poured into the housing and extruded under 4 bar nitrogen gas, 40 with the filtrate collected into 50mL tubes. The duration of each extrusion was timed and noted.

The filtration sequence was: 0.8µm, 0.4µm, 0.2µm, 0.2µm, 0.1µm and 0.1µm (i.e. single passes through the larger filters and two passes through the smaller 0.2 and 0.1µm filters), with the filtrate warmed back to 35°C between passes. The liposomes were extruded, with tabulated data is below:

5

Table 1

Pore size (µm)	Duration	Recovery (g)
0.8	<4 sec	28.19
0.4	<4 sec	26.91
0.2	50 sec	23.76
0.2	22 sec	21.77
0.1	12 minutes	20.18
0.1	4 minutes	19.47

10 The resulting extruded lipids were stored at +5°C. 15mL of 'Extruded Liposomes' were removed from the chilled stock and dispensed into a sterile 50mL tube within a MicroBiological Safety Cabinet. The size of the extruded liposomes was analysed using an ALV5000 photon correlation spectrometer. The average radius was determined to be 75.40 ± 0.86nm and the average peak width 22.21 ± 3.86nm, giving an average diameter of 150.80nm and polydispersity index of 0.087.

15 **Example 2: Formulation of PEGylated liposomes for topical administration**

PEGylated Liposomes in citrate buffer were produced in accordance with Example 1 above according to the method of Baru *et al.* (2005). The Liposome formulation had the following composition; 50mM sodium citrate pH 7.0 containing 100mM phospholipids; comprising a 97:3 molar ratio mixture of palmitoyl-oleoylphosphatidylcholine (POPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-20 N-[poly-(ethyleneglycol)-2000] (DSPE-PEG 2000).

Exemplary topical formulations may be prepared according to the following:

Table 2

Ingredient	Percentage; g per 100g
Soy Phosphatidylcholine	6.680
Polysorbate 80 (Tween® 80)	0.850
Benzylalcohol	0.525
Methyl-4-hydroxybenzoate	0.250
Ethyl-4-hydroxybenzoate	0.250
Butylhydroxytoluene	0.020
Linalool	0.100

Ingredient	Percentage; g per 100g
mPEG-DSPE-2,000 Mw	0.760
Disodium EDTA	0.100
Disodium hydrogen orthophosphate 12 H ₂ O	0.061
Sodium dihydrogen orthophosphate 2 H ₂ O	0.755
Glycerol	3.000
Ethanol *	3.081
Sodium hydroxide	0.630
Carbopol 974P NF	1.250
Water	81.688
Total	100.000
<hr/>	
pH	7.5

Example 3: PEGylated liposomes for topical administration and treatment of mild to moderate haemophilia A

- 5 The test subject is dosed in order to potentiate the effects of endogenous Factor VIII in mild to moderate haemophilia A.

Following dosing of the subject with the PEGylated liposomes, the test subject is observed for clinical signs. Unexpected toxicities are screened for by performing CBC and serum chemistry tests at 48hr 10 and 5 days post-dose. Fibrinogen, FDPs and the thrombin time (TT) are evaluated to test for increased thrombosis risk.

Blood samples (5 ml) are taken from the subject dosed SQ at the following times points after administration:

- 15 Pre-drug administration and at 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 hours post-dose.

Whole blood (non-citrated; 1 ml) is used for the whole blood clotting assay and the activated clotting 20 time assay. The remaining 4ml blood samples are transferred into tubes containing 0.109M tri-sodium citrate anticoagulant (9:1 v/v) on ice.

The activated Partial Thromboplastin Time (aPTT), Activated Clot Time (ACT) and Thromboelastogram (TEG) assays are conducted on the citrated whole blood.

Plasma is prepared by centrifugation of the remaining citrated blood and the resulting plasma samples are stored in aliquots of approximately 100 μ l at -80°C.

Assays

5 (i) Non-citrated whole blood: Whole blood clotting assay

Blood samples are divided between 2 vacutubes, (2 X 0.5 ml) and observed carefully with periodic and judicious levelling of the tube until a clot was determined by interruption of flow in the fully horizontal position. The quality of the clot is observed by holding the tube in the fully inverted position. The whole blood clotting time was recorded as the mean of the total time from sample extraction until 10 visual observation of blood clot for both samples and the quality of the clot in the inverted position is noted.

(ii) Citrated whole blood: Thromboelastogram (TEG) assay

TEG is performed with re-calcified citrated whole blood using a Hemostasis Analyzer Model 5000 15 (Haemoscope Corporation) thromboelastograph according to the manufacturers' recommendations. Briefly, 1 ml of citrated whole blood is placed in a commercially available (Teg®Hemostasis System Kaolin, Haemonetics) vial containing kaolin. Mixing is ensured by gentle inversion of the kaolin-containing vials 5 times. Pins and cups are placed in the TEG analyzer in accordance with the standard procedure recommended by the manufacturer. Each standard TEG cup is placed in the 37° 20 C pre-warmed instrument holder and is filled with 20 μ l of calcium chloride (0.2 M). Then, 340 μ l of kaolin-activated citrated whole blood is added for a total volume of 360 μ l.

(iii) Activated Clotting Time (ACT) and activated Partial Thromboplastin Time (aPTT)

The ACT and aPTT tests are carried out using a Haemachron Jr coagulation analyzer (International 25 Technidyne Corps.) according to the manufacturer's instructions.

(iv) Plasma: FVIII activity assay (Chromogenic)

FVIII plasma activity is determined using the Coatest Assay (Dia Pharma, West Chester, OH). Plasma samples are diluted 1:20 to 1:80 with assay diluent and assayed according to the 30 manufacturer's instructions. Standard curves are established using normal hemostasis reference plasma (American Diagnostica Inc, Stamford, CT) and the purified FVIII protein.

(v) Plasma: FVIII ELISA

The concentration of FVIII antigen in plasma samples is determined by ELISA using the Visulize FVIII 35 antigen kit from Affinity Biologicals (Ancaster, Ontario, Canada) according to the manufacturer's instructions.

(vi) Plasma: Immunogenicity

Bethesda assays are conducted on 1:4, 1:10 and 1:20 dilutions of test plasma into FVIII deficient 40 human plasma. Equal volumes of the diluted test plasma and normal human reference plasma are

incubated at 37°C for 2 hours and the Bethesda titre determined using the aPTT assay and a normal human plasma standard curve as described above.

Example 4: Formulation of PEGylated liposomes for intravenous (IV) or subcutaneous (SQ) administration

PEGylated Liposomes in citrate buffer were produced in accordance with Example 1 above according to the method of Baru *et al.* (2005) comprising a mixture of palmitoyl-oleoylphosphatidylcholine (POPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[poly-(ethyleneglycol)-2000] (DSPE-MPEG 2000).

10

Exemplary SQ or IV formulations may be prepared according to the following:

Table 3

Substance	SQ/IV Formulation 9% Total Lipids (mg/mL)	SQ/IV Formulation 7% Total Lipids (mg/mL)	SQ/IV Formulation 4% Total Lipids (mg/mL)
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)	81	63	36
N-(Carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, sodium salt (MPEG-2000-DSPE)	9	7	4
Sodium citrate	9	9	9
Hydrochloric acid	q.s. (1)	q.s. (1)	q.s. (1)
Water	q.s. (2)	q.s. (2)	q.s. (2)
Total	1000	1000	1000

15 q.s.(1) - Quantity sufficient to adjust pH to 6.

q.s.(2) - Quantity sufficient to adjust volume to 1mL

Example 5: Gel and spray formulations of PEGylated liposomes for topical administration with altered levels of surfactant

20 PEGylated Liposomes in citrate buffer were produced in accordance with Example 1 above according to the method of Baru *et al.* (2005) comprising a mixture of soy phosphatidylcholine (SPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[poly-(ethyleneglycol)-2000] (DSPE-MPEG 2000). The formulations were prepared to test different physical forms as a gel or spray for topical administration.

25

Table 4

Substance	Topical formulation (0.85% surfactant) (mg/mL)	Topical formulation (3.5% surfactant) - spray (mg/mL)	Topical formulation (3.5% surfactant) - gel (mg/mL)	Topical formulation (0.47% surfactant) (mg/mL)
Soy Phosphatidylcholine	68.700	64.516	64.516	71.460
Polysorbate 80	8.500	35.484	35.484	4.720
N-(Carbonyl-methoxypolyethylene glycol-2000)-1,2-distearyl-sn-glycero-3-phosphoethanolamine, sodium salt (MPEG-2000-DSPE)	7.6 to 9.0	7.6 to 9.0	7.6 to 9.0	7.6 to 9.0
Benzyl alcohol	5.250	5.250	5.250	5.250
Methylparaben	2.500	2.500	2.500	7.500
Ethylparaben	2.500	1.700	1.700	0.000
Propylparaben	0.000	0.000	0.000	2.500
Butylhydroxyanisol	0.000	0.200	0.200	0.200
Butylhydroxytoluol	0.200	0.000	0.000	0.000
Linalool	1.000	1.000	1.000	1.000
Sodium metabisulphite	0.500	0.000	0.000	0.000
Disodium edetate	1.000	3.000	3.000	3.000
diSodium hydrogen orthophosphate dodecahydrate	7.550	7.720	7.720	7.720
Sodium dihydrogen orthophosphate dihydrate	0.610	4.440	4.440	4.440
Glycerol	30.000	30.000	30.000	50.000
Ethanol	36.510	30.000	30.000	30.000
Sodium hydroxide	6.300	0.000	0.000	0.000
Trometamol (TRIS)	0.000	0.000	12.677	0.000
Carbopol 974P NF	12.500	0.000	10.000	0.000
Water	q.s. to 1mL	q.s. to 1mL	q.s. to 1mL	q.s. to 1mL
Total	1000.000	1000.000	1000.000	1000.000

q.s. – Quantity sufficient to adjust volume to 1mL.

CLAIMS

1. A composition comprising a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer for use in medicine, wherein said composition does not contain any pharmaceutically active agent.
5
2. The composition for use of claim 1 wherein the colloidal particles are substantially neutral and the polymer carries substantially no net charge.
3. The composition for use of claim 1 wherein the colloidal particle has a mean particle 10 diameter of between about 0.03 to about 0.4 microns (μm).
4. The composition for use of claim 3 wherein the colloidal particle has a mean particle diameter of approximately 0.1 microns (μm).
15
5. The composition for use of any of claims 1 to 4 wherein said amphipathic lipid is a phospholipid from natural or synthetic sources.
20
6. The composition for use of claim 5 wherein said amphipathic lipid is a phosphatidylethanolamine (PE).
7. The composition for use of any of claims 1 to 4 wherein said amphipathic lipid is a carbamate-linked uncharged lipopolymer.
25
8. The composition for use of claim 7 wherein said amphipathic lipid is aminopropanediol distearoyl (DS).
9. The composition for use of claim 1 wherein said colloidal particles further comprise a second amphipathic lipid obtained from either natural or synthetic sources.
30
10. The composition for use of claim 9 wherein said second amphipathic lipid is a phosphatidylcholine.
11. The composition for use of claim 10 wherein the colloidal particle comprises palmitoyl-oleoyl phosphatidyl choline (POPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine 35 (DSPE) in a ratio (POPC:DSPE) of from 85 to 99:15 to 1.
12. The composition for use of claim 11 wherein the ratio of POPC:DSPE is from 90 to 99:10 to 1.
40
13. The composition for use of claim 12 wherein the ratio of POPC:DSPE is 97:3.

14. The composition for use of claim 9 wherein cholesterol is supplemented to the composition.
- 5 15. The composition for use of any one of claims 1 to 14 wherein said biocompatible hydrophilic polymer is selected from the group consisting of polyalkylethers, polylactic acids and polyglycolic acids.
16. The composition for use of claim 15 wherein said biocompatible hydrophilic polymer is
10 polyethylene glycol.
17. The composition for use of claim 16 wherein the polyethylene glycol has a molecular weight of between about 500 to about 5000 Daltons.
- 15 18. The composition for use of claim 17 wherein the polyethylene glycol has a molecular weight of approximately 2000 Daltons.
19. The composition for use of any one of claims 16 to 18 wherein the derivatized amphipathic lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[poly-(ethyleneglycol)].
- 20 20. The composition for use of any one of claims 16 to 18 wherein the derivatized amphipathic lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[poly-(ethyleneglycol)-2000] (DSPE-PEG 2000).
- 25 21. The composition for use of any one of claims 1 to 20 wherein the composition is for use in the treatment of a blood factor disease, an endocrine disorder or a hormone deficiency.
22. A method of treatment of a patient suffering from a disease or trauma comprising administering to said patient a composition as defined in any one of claims 1 to 21.
- 30 23. The method of treatment of claim 22 wherein the disease is a blood factor disease, an endocrine disorder or a hormone deficiency.
24. A kit of parts comprising a composition of any one of claims 1 to 21 and an administration
35 vehicle including injectable solutions for administration.
25. A dosage form of a pharmaceutical composition of any one of claims 1 to 21.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2016/074759

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K9/00 A61K9/127
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PENG AARON ET AL: "PEGylation of a Factor VIII-Phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice", THE AAPS JOURNAL, SPRINGER US, BOSTON, vol. 14, no. 1, 16 December 2011 (2011-12-16), pages 35-42, XP035719227, DOI: 10.1208/S12248-011-9309-2 [retrieved on 2011-12-16] the whole document ----- US 2007/167359 A1 (BARU MOSHE [IL] ET AL) 19 July 2007 (2007-07-19) paragraphs [0010] - [0026]; claims; figures 1-11; examples ----- -----	1-25 1-25 -/-
X		

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
14 December 2016	22/12/2016
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Ceyte, Mathilde

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2016/074759

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BARU MOSHE ET AL: "Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy", THROMBOSIS AND HAEMOSTASIS, SCHATTAUER GMBH, DE, vol. 93, no. 6, 1 June 2005 (2005-06-01), pages 1061-1068, XP008159062, ISSN: 0340-6245, DOI: 10.1160/TH04-08-0485 the whole document -----	1-25
X	US 2003/232075 A1 (NELSESTUEN GARY L [US]) 18 December 2003 (2003-12-18) claims; examples paragraph [0040] -----	1-25
A	YATUV R ET AL: "Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 135, no. 1, 2 April 2009 (2009-04-02), pages 44-50, XP025969922, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2008.12.004 [retrieved on 2009-03-10] the whole document -----	1-25
X	US 2007/141135 A1 (BALU-LYER SATHY V [US] ET AL) 21 June 2007 (2007-06-21) paragraphs [0008] - [0023] claims; figures; examples -----	1-25
1		

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2016/074759

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 2007167359	A1	19-07-2007	AT 395101 T		15-05-2008
			AU 2004229253 A1		28-10-2004
			BR PI0409424 A		25-04-2006
			CA 2522179 A1		28-10-2004
			CN 1774281 A		17-05-2006
			DK 1633440 T3		08-09-2008
			EP 1633440 A1		15-03-2006
			ES 2307009 T3		16-11-2008
			JP 2006523683 A		19-10-2006
			MX PA05010926 A		25-11-2005
			PT 1633440 E		25-08-2008
			US 2007167359 A1		19-07-2007
			WO 2004091723 A1		28-10-2004
<hr style="border-top: 1px dashed black;"/>					
US 2003232075	A1	18-12-2003	NONE		
<hr style="border-top: 1px dashed black;"/>					
US 2007141135	A1	21-06-2007	AU 2006263566 A1		04-01-2007
			BR PI0612843 A2		30-11-2010
			CA 2613705 A1		04-01-2007
			CN 101304757 A		12-11-2008
			EP 1898939 A2		19-03-2008
			JP 2008544990 A		11-12-2008
			NZ 565039 A		30-04-2010
			US 2007141135 A1		21-06-2007
			WO 2007002886 A2		04-01-2007
<hr style="border-top: 1px dashed black;"/>					